PsyBio Therapeutics Corp (PSYBF)
OTC
Healthcare
Biotechnology
$0.00
▲ +0.00%
Market Cap
$1,275
Sector
Healthcare
Industry
Biotechnology
Beta
0.49
52-Wk Range
0.00001-0.005
CEO
Evan Levine
Country
US
Currency
USD
PsyBio Therapeutics Corp operates in the Biotechnology industry of the Healthcare sector, headquartered in Denver, CO, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $1,275. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of 0.49 implies it has historically moved less than the broad market.
Valuation & profitability (TTM)
P/E
-0.00
Price / Sales
0.00
Price / Book
-0.00
EV / EBITDA
-0.03
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
-0.09
Current ratio
0.13
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
118
IPO date
2021-04-23
Headquarters
Denver, CO, US
About PsyBio Therapeutics Corp
PsyBio Therapeutics Corp. engages in the development of drugs intended for the treatment of mental health challenges and other disorders. The company was founded on October 28, 2009 and is headquartered in Sunrise, FL.
Comparable companies
PsyBio Therapeutics Corp is most often compared with the following Healthcare names:
More research on PSYBF
Open full interactive analysis & DCF →